Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.

Antiviral therapy - 1 Jan 2008

Carrouée-Durantel Sandra, Durantel David, Werle-Lapostolle Bettina, Pichoud Christian, Naesens Lieve, Neyts Johan, Trépo Christian, Zoulim Fabien

Abstract excerpt

BACKGROUND: Adefovir dipivoxil (ADV) has demonstrated activity against wild-type and lamivudine-resistant hepatitis B virus (HBV). After 1 year of therapy, a median 3.5-4.0 log10 decrease in viral load is observed. Our aim was to characterize the different profiles of response to ADV in relation to the in vitro susceptibility of viral strains to ADV. METHODS: In an international Phase III randomized,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Organophosphonates

Share to Patient Compliance

Share to Reverse Transcriptase Inhibitors

Share to Treatment Failure

Share to Viral Load

Source

Identifiers

PMID: 18572751

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.PMID 18572751Read ↗

Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.Semantic proximity Read ↗

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.Semantic proximity Read ↗

Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.Semantic proximity Read ↗

Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B.Semantic proximity Read ↗

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.Semantic proximity Read ↗

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].Semantic proximity Read ↗

Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.Semantic proximity Read ↗

Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.Semantic proximity Read ↗

Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.